Molecular Modeling and Drug Discovery Lab, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy.
Analytical Chemistry and in Vivo Pharmacology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy.
J Med Chem. 2020 Apr 9;63(7):3508-3521. doi: 10.1021/acs.jmedchem.9b01760. Epub 2020 Mar 30.
We previously reported a first set of hybrid topoisomerase II (topoII) poisons whose chemical core merges key pharmacophoric elements of etoposide and merbarone, which are two well-known topoII blockers. Here, we report on the expansion of this hybrid molecular scaffold and present 16 more hybrid derivatives that have been designed, synthesized, and characterized for their ability to block topoII and for their overall drug-like profile. Some of these compounds act as topoII poison and exhibit good solubility, metabolic (microsomal) stability, and promising cytotoxicity in three cancer cell lines (DU145, HeLa, A549). Compound (ARN24139) is the most promising drug-like candidate, with a good pharmacokinetics profile . Our results indicate that this hybrid new chemical class of topoII poisons deserves further exploration and that is a favorable lead candidate as a topoII poison, meriting future studies to test its efficacy in tumor models.
我们之前报道了一组新型的拓扑异构酶 II(topoII)混合抑制剂,其化学核心融合了依托泊苷和米托蒽醌这两种著名的拓扑异构酶 II 抑制剂的关键药效团元素。在这里,我们扩展了这个混合分子支架,并设计、合成了 16 个更多的混合衍生物,对其抑制拓扑异构酶的能力和整体类药性进行了表征。其中一些化合物作为拓扑异构酶 II 抑制剂,具有良好的溶解性、代谢(微粒体)稳定性和在三种癌细胞系(DU145、HeLa、A549)中良好的细胞毒性。化合物 (ARN24139) 是最有前途的类药性候选药物,具有良好的药代动力学特性。我们的研究结果表明,这种新型拓扑异构酶 II 抑制剂的混合化学类值得进一步探索,化合物 是一种有前途的拓扑异构酶 II 抑制剂先导候选药物,值得进一步研究其在肿瘤模型中的疗效。